ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 8, 2011, Pages 1237-1244

  Pidala, Joseph ^a,b   Tomblyn, Marcie ^a,b   Nishihori, Taiga ^a,b   Ayala, Ernesto ^a,b   Field, Teresa ^a,b   Fernandez, Hugo ^a,b   Perez, Lia ^a,b   Locke, Fred ^a,b   Alsina, Melissa ^a,b   Ochoa, Jose Leonel ^a,b   Perkins, Janelle ^a,b   Tate, Cheryl ^a   Shapiro, Jamie ^a   Conwell, Michelle ^a   Bookout, Ryan ^a   Anasetti, Claudio ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Acute graft versus host disease; Antithymocyte globulin; Mismatched unrelated donor transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; HLA ANTIGEN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG EFFICACY; ENGRAFTMENT; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION COMPLICATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PROPHYLAXIS; RELAPSE; RETROSPECTIVE STUDY; VIRUS REACTIVATION;

ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RABBITS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 79960323788     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.12.705     Document Type: Article

References (51)

1. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005, 35:225-231.
2. Mohty M. Mechanisms of action of antithymocyte globulin:T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
3. Bacigalupo A, Lamparelli T, Milone G, et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant, 45:385-391.
4. Bacigalupo A., Oneto R., Lamparelli T., et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 2001, 28:1093-1096.
5. Macmillan M.L., Couriel D., Weisdorf D.J., et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007, 109:2657-2662.
6. Dugan M.J., DeFor T.E., Steinbuch M., Filipovich A.H., Weisdorf D.J. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival. Ann Hematol 1997, 75:41-46.
7. Arai S., Margolis J., Zahurak M., Anders V., Vogelsang G.B. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002, 8:155-160.
8. Khoury H., Kashyap A., Adkins D.R., et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001, 27:1059-1064.
9. MacMillan M.L., Weisdorf D.J., Davies S.M., et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:40-46.
10. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991, 77:1821-1828.
11. Ayuk F., Diyachenko G., Zabelina T., et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol 2008, 36:1047-1054.
12. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002, 30:681-686.
13. Kim H.J., Min W.S., Cho B.S., et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009, 15:704-717.
14. Kroger N., Zabelina T., Binder T., et al. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant 2009, 15:454-462.
15. Zander A.R., Kroger N., Schleuning M., et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003, 32:355-361.
16. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
17. Ramsay N.K., Kersey J.H., Robison L.L., et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982, 306:392-397.
18. Weiden P.L., Doney K., Storb R., Thomas E.D. Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation 1979, 27:227-230.
19. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
20. Champlin R.E., Perez W.S., Passweg J.R., et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007, 109:4582-4585.
21. Toor A., Rodriguez T., Bauml M., et al. Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT. Bone Marrow Transplant 2008, 42:723-731.
22. Schleuning M., Gunther W., Tischer J., Ledderose G., Kolb H.J. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003, 32:243-250.
23. Bonifazi F., Bandini G., Rondelli D., et al. Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. Bone Marrow Transplant 2003, 32:237-242.
24. Meijer E., Bloem A.C., Dekker A.W., Verdonck L.F. Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell-depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts. Transplantation 2003, 75:1910-1913.
25. Finke J., Schmoor C., Lang H., Potthoff K., Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 2003, 21:506-513.
26. Remberger M., Storer B., Ringden O., Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002, 29:391-397.
27. Tanosaki R., Uike N., Utsunomiya A., et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 2008, 14:702-708.
28. Bonifazi F., Bandini G., Stanzani M., et al. In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. Bone Marrow Transplant 2005, 35:1025-1026.
29. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
30. Bacigalupo A., Lamparelli T., Gualandi F., et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002, 8:656-661.
31. Thomson B.G., Robertson K.A., Gowan D., et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 2000, 96:2703-2711.
32. Fehse N., Fehse B., Kroger N., et al. Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. J Hematother Stem Cell Res 2003, 12:237-242.
33. Juvonen E., Aalto S.M., Tarkkanen J., et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003, 32:97-102.
34. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
35. Reddy N., Rezvani K., Barrett A.J., Savani B.N. Strategies to prevent EBV reactivation and post-transplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high risk patients. Biol Blood Marrow Transplant 2010.
36. van Esser J.W., van der Holt B., Meijer E., et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001, 98:972-978.
37. Ahmad I., Cau N.V., Kwan J., et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 2009, 87:1240-1245.
38. Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant. 16:287-291.
39. van Esser J.W., Niesters H.G., van der Holt B., et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002, 99:4364-4369.
40. Weinstock D.M., Ambrossi G.G., Brennan C., Kiehn T.E., Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006, 37:539-546.
41. Ayuk F., Diyachenko G., Zabelina T., et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:913-919.
42. Hamadani M., Blum W., Phillips G., et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009, 15:1422-1430.
43. Meijer E., Cornelissen J.J., Lowenberg B., Verdonck L.F. Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol 2003, 31:1026-1030.
44. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
45. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
46. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
47. Brennan D.C., Flavin K., Lowell J.A., et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999, 67:1011-1018.
48. Gaber A.O., First M.R., Tesi R.J., et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998, 66:29-37.
49. Hardinger K.L., Rhee S., Buchanan P., et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008, 86:947-952.
50. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
51. Small T.N.K.N., Jakubowski A., Young J.W., Prockop S., Perales M.-A., O'Reilly R.J., Papadopoulos E.B. Pilot trial of rituximab for the prevention of Epstein Barr Virus B cell lymphoproliferative disorder (EBV-LPD) following T cell depleted (TCD) unrelated or HLA-mismatched related hemato-poietic stem cell transplantation. Blood 2006, 108:2922.